287 related articles for article (PubMed ID: 11830889)
1. [Drug therapy of multiple sclerosis].
Kinnunen E
Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
[No Abstract] [Full Text] [Related]
2. Seeing injectable ms therapies differently: they are more similar than different.
Johnson KP; Fox RJ; Arnold DL
Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
[No Abstract] [Full Text] [Related]
3. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
4. [New therapeutic methods in the treatment of multiple sclerosis].
Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
[No Abstract] [Full Text] [Related]
5. Glatiramer and suspected multiple sclerosis. No proven advantage.
Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
[No Abstract] [Full Text] [Related]
6. Patient and family fact sheet. Current treatments for multiple sclerosis.
Kernich CA
Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335
[No Abstract] [Full Text] [Related]
7. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
[No Abstract] [Full Text] [Related]
8. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski R; Stürzebecher CS; Kapp JF
Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
[No Abstract] [Full Text] [Related]
10. [Interferon beta-1a].
Taéron C
Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
[No Abstract] [Full Text] [Related]
11. [Betaferon and therapy of multiple sclerosis--present and future].
Hohlfeld R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
[No Abstract] [Full Text] [Related]
12. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111
[No Abstract] [Full Text] [Related]
13. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
14. 10 years of interferon beta-1b (Beta feron therapy.
Kappos L; Hartung HP
J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
[No Abstract] [Full Text] [Related]
15. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
Losy J
Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302
[TBL] [Abstract][Full Text] [Related]
16. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
17. Combination therapy for treatment of multiple sclerosis.
Lublin FD; Reingold SC
Ann Neurol; 1998 Jul; 44(1):7-9. PubMed ID: 9667587
[No Abstract] [Full Text] [Related]
18. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
Oger J; Gibbs E
Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
[No Abstract] [Full Text] [Related]
19. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
20. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
